News

The use of Ultomiris (ravulizumab) led to stronger reductions in generalized myasthenia gravis (gMG) symptoms for people who had been living with the disease for no more than two years, new analyses from the CHAMPION MG trial indicated. “Overall, our analysis suggests that treatment of gMG with [Ultomiris]…

Ultomiris (ravulizumab) treatment led to sustained reductions in generalized myasthenia gravis (gMG) symptom severity and acute clinical worsening events for more than a year, according to new analyses from the CHAMPION MG clinical trial and its open-label extension (OLE). The analyses were presented at the Muscular Dystrophy Association’s…

Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) in patients regardless of their disease length, treatment history, or acetylcholine receptor (AChR) antibody status, according to two new analyses from the ADAPT clinical trial and its open-label extension, ADAPT+. These findings serve to reinforce “the efficacy of efgartigimod…

Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR)-targeting antibodies. “We are pleased to announce this latest regulatory approval of Vyvgart, another exciting advancement toward our vision of making our…

High levels of anti-acetylcholine receptor (AChR) antibodies — the most common self-reactive antibodies known to drive myasthenia gravis (MG) — in people with ocular MG are linked to greater odds of developing generalized MG, according to a recent study. People with ocular MG who had high anti-AChR antibody…

Repetitive nerve stimulation (RNS), a standard tool used to diagnose myasthenia gravis (MG), was unable to predict disease severity over the long term, or other MG outcomes, among people with the neuromuscular condition, a study found. While there was a correlation between RNS results and disease severity at symptom…

Batoclimab (HBM9161) eased the symptoms of generalized myasthenia gravis (gMG) and their impact on daily function, hitting the main and secondary goals of a Phase 3 clinical trial in China. No new side effects arose during the trial (NCT05039190) and the experimental therapy, which is being developed by…

Ad Scientiam has launched a program to develop and validate new digital biomarkers for self-assessing patients with generalized myasthenia gravis (gMG). The launch was announced on Rare Disease Day, Feb. 28, and is supported by Alexion, AstraZeneca Rare Disease. “Easy-to-use digital tools have the potential to generate reliable…

The ad hoc All United for MG coalition has established European Myasthenia Gravis Day — set for June 2 — to raise awareness of the neuromuscular autoimmune disease, and to call attention to the needs of this community of patients in Europe. The day will fall at the start of…

Thymus removal surgery is generally safe for the majority of elderly people who have myasthenia gravis (MG), a study in China found. In fact, all patients ages 65 and older in the study were safely discharged and did not need to stay longer in the hospital. Nonetheless, according to…